BACKGROUND: Randomized controlled trials have reported lower mortality among patients who adhere to placebo compared with those who do not. We explored this phenomenon by reanalyzing data from the placebo arm of the Beta Blocker Evaluation of Survival Trial (BEST), a randomized, double-blind, placebo-controlled trial of bucindolol and mortality. AIMS: Our primary aim was to measure and explain the association between adherence to placebo and total mortality among the placebo-allocated participants in the BEST trial. Secondary aims included assessment of the association between placebo adherence and cause-specific mortality. METHODS: Participants with "higher placebo adherence" were defined as having taken at least 75% of their placebo study medication over the entire course of each individual's participation in the study, while those with "lower placebo adherence" took <75%. Primary outcome was in-study all-cause mortality. To account for confounding, we adjusted for all available modifiable, non-modifiable and psychosocial variables. RESULTS: Adherent participants had a significantly lower total mortality compared to less-adherent participants (HR=0.61, 95% Confidence Interval: 0.46-0.82). Adjusting for available confounders did not change the magnitude or significance of the estimates. When considering cause-specific mortality, CVD and pump failure showed similar associations. CONCLUSIONS: Analyses of the BEST trial data support a strong association between adherence to placebo study medication and total mortality. While probably not due to publication bias or simple confounding by healthy lifestyle factors, the underlying explanation for the association remains a mystery. Prospective examination of this association is necessary to better understand the underlying mechanism of this observation.
RCT Entities:
BACKGROUND: Randomized controlled trials have reported lower mortality among patients who adhere to placebo compared with those who do not. We explored this phenomenon by reanalyzing data from the placebo arm of the Beta Blocker Evaluation of Survival Trial (BEST), a randomized, double-blind, placebo-controlled trial of bucindolol and mortality. AIMS: Our primary aim was to measure and explain the association between adherence to placebo and total mortality among the placebo-allocated participants in the BEST trial. Secondary aims included assessment of the association between placebo adherence and cause-specific mortality. METHODS:Participants with "higher placebo adherence" were defined as having taken at least 75% of their placebo study medication over the entire course of each individual's participation in the study, while those with "lower placebo adherence" took <75%. Primary outcome was in-study all-cause mortality. To account for confounding, we adjusted for all available modifiable, non-modifiable and psychosocial variables. RESULTS: Adherent participants had a significantly lower total mortality compared to less-adherent participants (HR=0.61, 95% Confidence Interval: 0.46-0.82). Adjusting for available confounders did not change the magnitude or significance of the estimates. When considering cause-specific mortality, CVD and pump failure showed similar associations. CONCLUSIONS: Analyses of the BEST trial data support a strong association between adherence to placebo study medication and total mortality. While probably not due to publication bias or simple confounding by healthy lifestyle factors, the underlying explanation for the association remains a mystery. Prospective examination of this association is necessary to better understand the underlying mechanism of this observation.
Authors: D Obias-Manno; E Friedmann; M M Brooks; S A Thomas; C Haakenson; M Morris; F Wimbush; C Somelofski; F Goldner Journal: Ann Epidemiol Date: 1996-03 Impact factor: 3.797
Authors: J Irvine; B Baker; J Smith; S Jandciu; M Paquette; J Cairns; S Connolly; R Roberts; M Gent; P Dorian Journal: Psychosom Med Date: 1999 Jul-Aug Impact factor: 4.312
Authors: Bradi B Granger; Karl Swedberg; Inger Ekman; Christopher B Granger; Bertil Olofsson; John J V McMurray; Salim Yusuf; Eric L Michelson; Marc A Pfeffer Journal: Lancet Date: 2005-12-10 Impact factor: 79.321
Authors: R I Horwitz; C M Viscoli; L Berkman; R M Donaldson; S M Horwitz; C J Murray; D F Ransohoff; J Sindelar Journal: Lancet Date: 1990-09-01 Impact factor: 79.321
Authors: Andrew L Avins; Alice Pressman; Lynn Ackerson; Peter Rudd; John Neuhaus; Eric Vittinghoff Journal: J Gen Intern Med Date: 2010-08-13 Impact factor: 5.128
Authors: Amy M Padula; Alice R Pressman; Eric Vittinghoff; Deborah Grady; John Neuhaus; Lynn Ackerson; Peter Rudd; Andrew L Avins Journal: Am J Med Date: 2012-08 Impact factor: 4.965
Authors: Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani Journal: Cochrane Database Syst Rev Date: 2020-02-27